Type 2 diabetes mellitus patients treated with either the sodium-glucose cotransporter-2 inhibitor empagliflozin or dipeptidyl peptidase 4 inhibitors incur similar overall healthcare costs, according to data from the EMPRISE trial presented at the 79th Scientific Sessions of the American Diabetes Association (ADA 2019).
Supplementation with vitamin D among vitamin D-sufficient adults who are at high risk of developing diabetes does not reduce the risk of developing the disease vs placebo, according to the randomized, placebo-controlled D2d* trial.
Once-weekly subcutaneous injections of dulaglutide in patients with type 2 diabetes (T2D) reduced cardiovascular (CV) events, particularly non-fatal stroke, regardless of their CV history in the longest cardiovascular outcomes trial (CVOT) to date for a GLP-1* receptor agonist, REWIND**. The CV benefits come with potential renal benefits, with the largest effect seen for macroalbuminuria in an exploratory analysis.
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
mechanisms for its cardiovascular benefits.
Zinc supplementation significantly lowers key glycaemic indicators, particularly fasting glucose (FG) in individuals with diabetes and in those who received an inorganic supplement, results of a systematic review and meta-analysis have shown.
Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.
By reducing hepatic enzyme levels and improving markers of hepatic steatosis or fibrosis, bariatric surgery may help reduce the risk of non-alcoholic fatty liver disease (NAFLD), according to a study from Portugal presented at ENDO 2020.